Who owns Spyre Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of SYRE from SEC Form 13F filings across 268 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 268 institutions disclosed 95.8M shares of Spyre Therapeutics, Inc. worth $8.52B — about 113.1% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
268
13F holders
$8.52B
value, 2026 filers
113.1%
of shares outstanding (95.8M sh)
92
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of SYRE's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 13.0M | $1.16B | 0.1% | 15.4% | +10.6% |
| 2 | BlackRock, Inc. | 6.5M | $577.7M | 0.0% | 7.7% | +17.8% |
| 3 | PERCEPTIVE ADVISORS LLC | 4.3M | $383.5M | 5.8% | 5.1% | +14.2% |
| 4 | RTW INVESTMENTS, LP | 4.3M | $377.5M | 3.2% | 5% | +1.9% |
| 5 | Paradigm Biocapital Advisors LP | 3.8M | $341.0M | 6.4% | 4.5% | +96.2% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3.4M | $306.2M | 0.0% | 4.1% | +12.8% |
| 7 | STATE STREET CORP | 3.1M | $271.4M | 0.0% | 3.6% | +17.3% |
| 8 | Venrock Adviser, LLC | 3.0M | $265.0M | 8.0% | 3.5% | -19.0% |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.0M | $262.9M | 0.0% | 3.5% | +85.2% |
| 10 | Driehaus Capital Management LLC | 2.8M | $248.5M | 1.4% | 3.3% | +0.3% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 2.6M | $239.3M | 0.0% | 3% | +48.9% |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.3M | $206.9M | 0.0% | 2.8% | +298.2% |
| 13 | Capital World Investors | 2.3M | $205.6M | 0.0% | 2.7% | +247.4% |
| 14 | Jupiter Topco LLCNEW | 2.2M | $195.9M | 0.1% | 2.6% | new |
| 15 | TCG Crossover Management, LLC | 1.9M | $168.7M | 4.1% | 2.2% | 0.0% |
| 16 | TANG CAPITAL MANAGEMENT LLC | 1.9M | $168.0M | 7.6% | 2.2% | 0.0% |
| 17 | BANK OF AMERICA CORP /DE/ | 1.8M | $157.8M | 0.0% | 2.1% | +44.8% |
| 18 | ADAGE CAPITAL PARTNERS GP, L.L.C.NEW | 1.7M | $152.9M | 0.2% | 2% | new |
| 19 | WELLINGTON MANAGEMENT GROUP LLP | 1.6M | $140.4M | 0.0% | 1.9% | -13.3% |
| 20 | GOLDMAN SACHS GROUP INC | 1.5M | $131.2M | 0.0% | 1.7% | +447.6% |
| 21 | FRANKLIN RESOURCES INC | 1.5M | $130.8M | 0.0% | 1.7% | +66.8% |
| 22 | Remedium Capital Partners, LLC | 1.5M | $130.0M | 28.8% | 1.7% | +0.5% |
| 23 | Affinity Asset Advisors, LLC | 1.3M | $113.6M | 5.1% | 1.5% | 0.0% |
| 24 | JPMORGAN CHASE & CO | 1.1M | $98.9M | 0.0% | 1.3% | +11.6% |
| 25 | Holocene Advisors, LPNEW | 1.0M | $90.1M | 0.2% | 1.2% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.